[go: up one dir, main page]

ES2485615B8 - Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama - Google Patents

Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama Download PDF

Info

Publication number
ES2485615B8
ES2485615B8 ES201330179A ES201330179A ES2485615B8 ES 2485615 B8 ES2485615 B8 ES 2485615B8 ES 201330179 A ES201330179 A ES 201330179A ES 201330179 A ES201330179 A ES 201330179A ES 2485615 B8 ES2485615 B8 ES 2485615B8
Authority
ES
Spain
Prior art keywords
predict
recurrence
risk
products
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201330179A
Other languages
English (en)
Other versions
ES2485615B1 (es
ES2485615A1 (es
Inventor
Francisco Javier FREIRE SALINAS
Javier GÓMEZ ROMÁN
Saioa DOMÍNGUEZ HORMAETXE
Laureano Simón Buela
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncomatryx Biopharma SL
Original Assignee
Oncomatryx Biopharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomatryx Biopharma SL filed Critical Oncomatryx Biopharma SL
Priority to ES201330179A priority Critical patent/ES2485615B8/es
Priority to EP14712327.7A priority patent/EP2957913B1/en
Priority to US14/767,119 priority patent/US20150369808A1/en
Priority to PCT/ES2014/070094 priority patent/WO2014125144A1/es
Priority to ES14712327.7T priority patent/ES2628150T3/es
Publication of ES2485615A1 publication Critical patent/ES2485615A1/es
Publication of ES2485615B1 publication Critical patent/ES2485615B1/es
Application granted granted Critical
Publication of ES2485615B8 publication Critical patent/ES2485615B8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Image Analysis (AREA)

Abstract

Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama.#La presente invención se refiere a métodos y productos in vitro para pronosticar la evolución clínica o predecir el riesgo y tipo de recidiva de una lesión papilar de mama, en base a expresión de la proteína proCOL11A1, con el objetivo de determinar el tratamiento y patrón de seguimiento más adecuado para cada paciente.
ES201330179A 2013-02-12 2013-02-12 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama Active ES2485615B8 (es)

Priority Applications (5)

Application Number Priority Date Filing Date Title
ES201330179A ES2485615B8 (es) 2013-02-12 2013-02-12 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama
EP14712327.7A EP2957913B1 (en) 2013-02-12 2014-02-11 Methods and products for prognosing the clinical evolution, or predicting the recurrence risk, of a papillary lesion of the breast
US14/767,119 US20150369808A1 (en) 2013-02-12 2014-02-11 Methods and products for prognosing the clinical evolution, or predicting the recurrence risk, of a papillary lesion of the breast
PCT/ES2014/070094 WO2014125144A1 (es) 2013-02-12 2014-02-11 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama
ES14712327.7T ES2628150T3 (es) 2013-02-12 2014-02-11 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201330179A ES2485615B8 (es) 2013-02-12 2013-02-12 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama

Publications (3)

Publication Number Publication Date
ES2485615A1 ES2485615A1 (es) 2014-08-13
ES2485615B1 ES2485615B1 (es) 2015-04-27
ES2485615B8 true ES2485615B8 (es) 2015-06-05

Family

ID=50349639

Family Applications (2)

Application Number Title Priority Date Filing Date
ES201330179A Active ES2485615B8 (es) 2013-02-12 2013-02-12 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama
ES14712327.7T Active ES2628150T3 (es) 2013-02-12 2014-02-11 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES14712327.7T Active ES2628150T3 (es) 2013-02-12 2014-02-11 Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama

Country Status (4)

Country Link
US (1) US20150369808A1 (es)
EP (1) EP2957913B1 (es)
ES (2) ES2485615B8 (es)
WO (1) WO2014125144A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3110764B1 (fr) * 2020-05-20 2024-05-10 Quantum Surgical Méthode de prédiction de la récidive d’une lésion par analyse d’images

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080014594A1 (en) 2003-01-31 2008-01-17 Kevin Hestir Lung-Expressed Polypeptides
US9353415B2 (en) * 2006-12-19 2016-05-31 Thomson Reuters (Scientific) Llc Methods for functional analysis of high-throughput experimental data and gene groups identified therefrom
EP2483813A1 (en) * 2009-10-01 2012-08-08 Chipdx LLC System and method for classification of patients
ES2398328B1 (es) 2011-08-09 2014-02-05 Oncomatrix, S.L. Métodos y productos para el diagnóstico in vitro, pronóstico in vitro y desarrollo de fármacos contra carcinomas invasivos.

Also Published As

Publication number Publication date
ES2485615B1 (es) 2015-04-27
ES2485615A1 (es) 2014-08-13
ES2628150T3 (es) 2017-08-01
EP2957913A1 (en) 2015-12-23
EP2957913B1 (en) 2017-03-29
WO2014125144A1 (es) 2014-08-21
US20150369808A1 (en) 2015-12-24

Similar Documents

Publication Publication Date Title
DK3126490T3 (da) Kunstigt tredimensionalt brystvæv, fedtvæv og tumorsygdomsmodel
MX381503B (es) Métodos para la liberación de cromolina.
DK3027208T3 (da) Cancerdiagnose og -terapi, der involverer cancerstamceller
IL237592B (en) Methods of expanding and assessing b cells and using expanded b cells to treat disease
CA138749S (en) Shoe
IL244748B (en) Methods and processes for non-invasive assessment of genetic variations
HUE040044T2 (hu) Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
IL251530B (en) Use of cannabinoids in the treatment of degenerative skeletal muscle diseases
CL2015003704A1 (es) Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer
PT3481846T (pt) 24-hidroxiesteroides 11-substituídos para utilização no tratamento de afeções relacionadas com nmda
LT3386548T (lt) Inozitolio dariniai, skirti naudoti patologinėje kristalizacijoje
HUE046702T2 (hu) Eljárások üvegcsontbetegség kezelésére
HUE045724T2 (hu) GRPR antagonisták GRPR-pozitív rák kimutatására, diagnózisára és kezelésére
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
BR112014028307A2 (pt) método para identificar ligantes do receptor ahr tendo atividade terapêutica supressiva de sebo, e referidos ligantes
PT3365432T (pt) Terapêutica com células estaminais baseada em células estaminais derivadas de tecido adiposo
IL263103A (en) Methods for predicting therapeutic benefit of anti-cd19 therapy in patients
DK2931296T3 (da) Sygdomsbehandling, der involverer mucin
LT2958624T (lt) Transplantuotų pacientų transplantanto prieš šeiminiką ligos gydymas
WO2014107718A3 (en) Heat shock protein (hsp) inhibition and monitoring effectiveness thereof
HUE067047T2 (hu) Humán antitest aggrekanáz típusú ADAMTS specieszek ellen aggrekanázzal kapcsolatos betegségek terápiájára
ES2485615B8 (es) Métodos y productos para pronosticar la evolución clínica o predecir el riesgo de recidiva de una lesión papilar de mama
BR112014029426A2 (pt) diagrama de decisão terapêutica, e, método de prognosticar, diagnosticar, e/ou predizer o risco de doença cardiovascular em um indivíduo
RU2012144141A (ru) Способ оценки вероятности возникновенения переломов при остеопорозе у женщин

Legal Events

Date Code Title Description
PC2A Transfer of patent

Owner name: ONCOMATRIX BIOPHARMA, S.L.

Effective date: 20140416

FG2A Definitive protection

Ref document number: 2485615

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150427